<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Hypersensitivity reactions to macrolides, aminoglycosides, tetracyclines, clindamycin, and metronidazole
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Hypersensitivity reactions to macrolides, aminoglycosides, tetracyclines, clindamycin, and metronidazole
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Hypersensitivity reactions to macrolides, aminoglycosides, tetracyclines, clindamycin, and metronidazole
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Roland Solensky, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            N Franklin Adkinson, Jr, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Anna M Feldweg, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jan 28, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H3200659">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         This topic will review hypersensitivity (allergic) reactions to macrolides, aminoglycosides, tetracyclines,
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         , and
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         . Hypersensitivity reactions to other antibiotic classes, namely beta-lactams, sulfonamides, fluoroquinolones, and
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         , are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2073.html" rel="external">
          "Penicillin allergy: Immediate reactions"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/13535.html" rel="external">
          "Cephalosporin hypersensitivity: Clinical manifestations and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2080.html" rel="external">
          "Sulfonamide allergy in HIV-uninfected patients"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/83728.html" rel="external">
          "Hypersensitivity reactions to fluoroquinolones"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2083.html" rel="external">
          "Vancomycin hypersensitivity"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3200666">
         <span class="h1">
          OVERVIEW
         </span>
         <span class="headingEndMark">
          —
         </span>
         The antimicrobial groups discussed in this review cause hypersensitivity reactions relatively infrequently compared with penicillins, cephalosporins, sulfonamides, and fluoroquinolones [
         <a href="#rid1">
          1,2
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H8608706">
         <span class="h2">
          Types of hypersensitivity reactions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hypersensitivity reactions, or allergic reactions, are immunologic reactions to a drug. There are many types of hypersensitivity reactions, which are broadly divided into immediate and delayed reactions, based upon the time between the first administered dose and the appearance of signs or symptoms [
         <a href="#rid3">
          3
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Immediate reactions are defined as reactions that begin within one hour of the first administered dose. In reality, symptoms and signs may appear up to one to two hours later if the drug was taken orally or with food or other medications that slow absorption. The most common signs and symptoms of immediate reactions are urticaria (
         <a class="graphic graphic_picture graphicRef75230" href="/z/d/graphic/75230.html" rel="external">
          picture 1
         </a>
         and
         <a class="graphic graphic_picture graphicRef72519" href="/z/d/graphic/72519.html" rel="external">
          picture 2
         </a>
         ), pruritus, flushing, angioedema of the face, extremities, or laryngeal tissues (leading to throat tightness with stridor or rarely, asphyxiation), wheezing, nausea, abdominal cramping or diarrhea, and/or hypotension or shock. Immediate reactions can be caused by the formation of immunoglobulin E (IgE) to the causative drug, which can then activate mast cells and basophils in the presence of the drug. Some drugs can cause immediate reactions by directly or indirectly activating mast cells and basophils, without the presence of drug-specific IgE. Immediate-type skin testing is used to evaluate immediate reactions. (See
         <a class="local">
          'Allergy evaluation'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Delayed reactions begin later than one hour (and sometimes days) after the first dose. Many different reaction types are classified as delayed. The most common are maculopapular or morbilliform exanthems (
         <a class="graphic graphic_picture graphicRef54205" href="/z/d/graphic/54205.html" rel="external">
          picture 3
         </a>
         and
         <a class="graphic graphic_picture graphicRef70062" href="/z/d/graphic/70062.html" rel="external">
          picture 4
         </a>
         ). There is a lack of consensus about how best to evaluate patients with past maculopapular exanthems. Some allergy experts perform intradermal skin testing that is interpreted 24 to 72 hours after placement, with erythema and induration representing a positive reaction. Others only perform graded challenges to diagnose such reactions, which is the most common approach in the United States.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         There are several types of delayed hypersensitivity reactions that are uncommon but potentially life-threatening for which no testing is informative. Furthermore, testing can be dangerous because re-exposure can cause a recurrence of the reaction. Such reactions include Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome (DRESS/DiHS).
        </p>
        <p>
        </p>
        <p>
         The intent of discriminating between immediate and delayed drug reactions is to distinguish immediate reactions from other types, since immediate reactions can escalate to potentially life-threatening anaphylaxis if the patient is re-exposed to the causative drug, even in very small amounts.
        </p>
        <p>
         The classification and pathogenesis of drug hypersensitivity reactions are reviewed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2086.html" rel="external">
          "Drug hypersensitivity: Classification and clinical features"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2072.html" rel="external">
          "Drug allergy: Pathogenesis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8608945">
         <span class="h2">
          Clinical history
         </span>
         <span class="headingEndMark">
          —
         </span>
         Evaluation of a patient with a past drug reaction always begins with a careful clinical history and an assessment of the type of hypersensitivity reaction the patient most likely experienced. Important questions for the patient with drug allergy are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/2079.html" rel="external">
          "An approach to the patient with drug allergy", section on 'Clinical history'
         </a>
         .)
        </p>
        <p>
         A thorough history of the reaction is essential and usually constitutes the most useful element of the evaluation. Many patients labeled as allergic to a drug actually experienced nonallergic adverse reactions. Common examples include gastrointestinal side effects with macrolides and tetracyclines or photosensitivity with tetracyclines. In some cases, such patients should continue to avoid the causative drug, but they are not candidates for further allergy evaluation.
        </p>
        <p class="headingAnchor" id="H8608741">
         <span class="h2">
          Referral
         </span>
         <span class="headingEndMark">
          —
         </span>
         Referral to an allergy expert with experience in drug-allergic reactions is appropriate in any of the following situations:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The patient has reactions to numerous antibiotics, and treatment options are becoming limited.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The patient experienced a life-threatening reaction to a drug and requires advice about how best to prevent re-exposure and whether related antibiotics can be safely administered.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The patient experienced a serious reaction in the context of receiving multiple drugs (eg, perioperative anaphylaxis), and the cause of the reaction is not clear.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The patient has a high likelihood of needing future treatment with a certain drug due to the nature of his/her underlying medical problems.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H8608938">
         <span class="h2">
          Allergy evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The clinical history is the most important component of a drug allergy evaluation. Other tools that are widely used include immediate-type skin testing and graded challenge. These procedures should be performed by allergy specialists because they require experience to interpret correctly, and although they are considered safe interventions, there is a risk of inducing another allergic reaction. Skin testing and challenges should be performed in a setting prepared to treat possible severe reactions, including anaphylaxis. In addition, any procedure that involves the deliberate exposure of a patient to a substance to which he/she may be allergic should be undertaken by someone with specific training in these techniques.
        </p>
        <p class="headingAnchor" id="H8609129">
         <span class="h3">
          Immediate-type skin testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Skin testing (prick-puncture and intradermal) is helpful in the evaluation of immediate reactions to some drugs. Briefly, prick-puncture skin testing should be performed first, along with positive and negative controls. If prick-puncture tests are negative, they are followed by intradermal skin testing. Skin test results are recorded 15 minutes after placement in the skin. Skin testing techniques and patient preparation are described in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/5541.html" rel="external">
          "Overview of skin testing for IgE-mediated allergic disease", section on 'Prick/puncture method'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5541.html" rel="external">
          "Overview of skin testing for IgE-mediated allergic disease", section on 'Intradermal method'
         </a>
         .)
        </p>
        <p>
         Unlike skin testing for penicillin allergy, skin testing for allergy to the drugs discussed in this review is not standardized or validated, and allergy experts may have different approaches.
        </p>
        <p class="headingAnchor" id="H8609147">
         <span class="h3">
          Graded challenge
         </span>
         <span class="headingEndMark">
          —
         </span>
         Graded challenge procedures may be required in the evaluation of antibiotic hypersensitivity. Challenges are mentioned briefly here. Indications, contraindications, and protocols are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/2079.html" rel="external">
          "An approach to the patient with drug allergy", section on 'Graded challenge and drug provocation'
         </a>
         .)
        </p>
        <p>
         Graded challenge is used to exclude allergy to the medication in question and is
         <strong>
          most appropriate for a patient who is unlikely to be allergic
         </strong>
         to that drug.
        </p>
        <p>
         Graded challenge
         <strong>
          does not modify the allergic response
         </strong>
         to the drug or prevent recurrent reactions. Therefore:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients who tolerate a drug upon graded challenge prove that they are not allergic to it.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A challenge procedure in a patient with a possible IgE-mediated drug allergy could potentially induce anaphylaxis and should be performed by an allergy expert in a setting prepared to identify and manage possible reactions.
        </p>
        <p>
        </p>
        <p>
         Challenges with the drug in question should
         <strong>
          not
         </strong>
         be performed in patients whose past reactions involved exfoliation, blistering, or sloughing of the mucous membranes or skin (eg, erythema multiforme, SJS/TEN) or inflammation of internal organs (DRESS/DiHS), since even small amounts of the suspect drug can reactivate these reactions.
        </p>
        <p class="headingAnchor" id="H3201835">
         <span class="h1">
          MACROLIDES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Commonly used macrolide antibiotics include
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         , and
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         . Nonallergic adverse effects, such as QT interval prolongation and gastrointestinal symptoms, are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/474.html" rel="external">
          "Azithromycin and clarithromycin", section on 'Adverse reactions'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3201842">
         <span class="h2">
          Types of reactions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Allergic reactions due to macrolides are less common than reactions to beta-lactam antibiotics, sulfonamide antibiotics, and fluoroquinolones [
         <a href="#rid4">
          4,5
         </a>
         ]. Most patients reporting macrolide reactions prove not to have a serious allergy. If patients from the largest published series are combined (in which most or all subjects, skin test-positive and skin test-negative, undergo graded challenge), the cumulative rate of reactions upon challenge with the culprit drug in patients with history of convincing macrolide allergy was 5 percent (13 of 255 subjects), and most reactions were mild [
         <a href="#rid6">
          6-9
         </a>
         ].
        </p>
        <p>
         The following studies address specific types of reactions:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Immunoglobulin E (IgE)-mediated reactions to macrolides are rare and largely confined to anecdotal case reports [
         <a href="#rid10">
          10-14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The vast majority of skin reactions are maculopapular exanthems:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In an analysis of over 40 clinical trials of children treated with
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         for various bacterial infections, 29 of 2655 (1.1 percent) developed skin eruptions [
         <a href="#rid15">
          15
         </a>
         ]. Of note, this study was not designed to include control patients treated with placebo, and 1 percent is a common rate of skin eruption to placebo in other drug studies.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A retrospective analysis of a general practice database of 150,000 mostly adult patients over an 18-month period revealed an incidence of macrolide-related cutaneous reactions of 1.1 percent [
         <a href="#rid5">
          5
         </a>
         ]. Again, there was no placebo group for comparison.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Several large-scale pediatric trials have compared treatment of otitis media with
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         versus
         <a class="drug drug_general" data-topicid="8676" href="/z/d/drug information/8676.html" rel="external">
          amoxicillin-clavulanate
         </a>
         [
         <a href="#rid16">
          16-21
         </a>
         ]. The safety data in these studies reported rates of cutaneous eruptions 0.3 to 1.7 percent for azithromycin and 2.0 to 5.2 percent for amoxicillin-clavulanate.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3201849">
         <span class="h2">
          Cross-reactivity
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are substantial differences in structure among macrolides with different sized lactone rings, and one would not expect extensive cross-reactivity [
         <a href="#rid22">
          22
         </a>
         ]. However, the allergic determinants of macrolide molecules have not been identified.
        </p>
        <p>
         Data regarding allergic cross-reactivity among macrolides are limited to case reports and small series. In these, the majority of patients who reacted to one macrolide (mostly with delayed reactions) tolerated other macrolides, suggesting little allergic cross-reactivity [
         <a href="#rid23">
          23-26
         </a>
         ]. However, most patients were only challenged with a macrolide different from the one that caused the initial reaction. Although understandable, this approach is not sufficient to prove lack of cross-reactivity, because many patients will also tolerate the culprit drug if it is given again. To conclusively study cross-reactivity, challenges to both drugs should be performed in close temporal association, which is not typically done, but there are rare reports of patients demonstrating convincing allergic reactions to multiple different macrolides [
         <a href="#rid14">
          14,27
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3201856">
         <span class="h2">
          Evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         History is an essential first step in evaluating patients who report an allergy to macrolides. If the patient's history suggests an immunologic reaction, referral to an allergy expert may be appropriate, although this is usually not warranted in patients who report past allergic reactions
         <strong>
          only
         </strong>
         to macrolides, because there are multiple alternative groups of antibiotics. Possible exceptions to this include patients predisposed to sinopulmonary infections because macrolides are very useful for these infections. (See
         <a class="local">
          'Referral'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H3378193038">
         <span class="h3">
          Our approach
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest performing skin testing in patients whose past reactions had features of immediate reactions, such as pruritic rashes, urticaria, or angioedema. Others have argued that it is not sufficiently helpful and instead advocate performing challenge directly [
         <a href="#rid9">
          9,28
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the author's clinic,
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         is the only macrolide used for skin testing. We use the highest nonirritating concentration of azithromycin, which is 0.01 mg/mL (a 1:10,000 dilution of the commercially available 100 mg/mL intravenous [IV] formulation) [
         <a href="#rid29">
          29
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          Clarithromycin
         </a>
         is not commercially available in the United States in an IV formulation, and no data are available about using oral formulations of clarithromycin for skin testing. In countries where IV clarithromycin is available, studies have used concentrations ranging from 0.5 mg/mL to approximately 0.05 mg/mL (corresponding to a 1:100 to a 1:1000 dilution of the commercial formulation), which were reported as nonirritating in previously unexposed subjects [
         <a href="#rid8">
          8,30
         </a>
         ]. Of note, the study which used 0.05 mg/mL found 0.167 mg/mL to be irritating in some patients, so we suggest using the more dilute concentration.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We do not test with
         <a class="drug drug_general" data-topicid="9418" href="/z/d/drug information/9418.html" rel="external">
          erythromycin
         </a>
         , since it is used less commonly.
        </p>
        <p>
        </p>
        <p>
         Although the positive predictive value (PPV) of macrolide skin testing was low in the studies discussed below, we advise patients with positive skin test results to avoid the drugs in question, in part because there are usually equivalent alternative antibiotics. If they require treatment with a specific macrolide and there are no acceptable antibiotic alternatives, we administer it using a desensitization protocol, which has been described in the published literature [
         <a href="#rid27">
          27
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2071.html" rel="external">
          "Rapid drug desensitization for immediate hypersensitivity reactions"
         </a>
         .)
        </p>
        <p>
         In patients with negative macrolide skin testing, the first administration of the macrolide should be via graded challenge, since skin testing does not detect all patients at risk for recurrent reactions. The author's approach to macrolide challenges is described below, and a general discussion of challenges is found separately. (See
         <a class="medical medical_review" href="/z/d/html/2079.html" rel="external">
          "An approach to the patient with drug allergy", section on 'Graded challenge and drug provocation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3201870">
         <span class="h3">
          Studies of skin testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         The utility of immediate-type skin testing for IgE-mediated allergy to macrolides has significant limitations, as illustrated in the following studies [
         <a href="#rid6">
          6-9,29,31
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a series of 73 consecutive children with cutaneous reactions to
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         , reactions consisted of urticaria (62 percent), angioedema (18 percent), and maculopapular rash (19 percent) [
         <a href="#rid8">
          8
         </a>
         ]. There were no cases of anaphylaxis. Twenty children had immediate reactions, 49 had delayed reactions, and 4 had reactions of undetermined timing. All the children were skin tested (prick-puncture and intradermal, read at 20 minutes and 48 hours) using 0.5 mg/mL of IV clarithromycin, which was found to be the highest nonirritating concentration in 18 control subjects. All patients (except 9 who refused) underwent blinded five-day oral challenges, regardless of the skin test results. Of the 64 challenged subjects, 9 (14 percent) had positive intradermal skin tests at 20 minutes. No patient was positive on prick-puncture tests or 48-hour intradermal tests.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Overall, 4 of 64 patients (6 percent) reacted on challenge: two immediate (urticaria) and two delayed (day 3 and 4) reactions (maculopapular rashes). Three out of 9 skin test-positive patients and 1 of 55 skin test-negative patients reacted on challenge. Thus, based on these small numbers, skin testing had a PPV of 33 percent, negative predictive value (NPV) of 98 percent, sensitivity of 75 percent, and specificity of 90 percent. The authors did not report the skin test and challenge results according to the type of reaction (immediate versus delayed) the patients had originally.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The same investigators studied 58 additional children with history of
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         allergy (21 immediate reactors and 37 delayed reactors) and 19 with
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         allergy (6 immediate reactors and 13 delayed reactors) [
         <a href="#rid31">
          31
         </a>
         ]. All the patients underwent skin testing, using 0.5 mg/mL IV clarithromycin and 0.1 mg/mL IV azithromycin. Unlike the previous study, only skin test-negative patients were challenged with five days of the culprit macrolide. In the clarithromycin group, 7 of 58 (12 percent) had positive skin tests (2 of 21 immediate reactors, 5 of 37 delayed reactors). Among the skin test-negative subjects, 2 of 51 had positive challenges (0 of 19 immediate reactors, 2 of 32 delayed reactors). In the azithromycin group, 9 of 19 (47 percent) had positive skin tests (4 of 6 immediate reactors, 5 of 13 delayed reactors). None of the 10 skin test-negative patients reacted to challenge. Therefore, a higher proportion of children were diagnosed with azithromycin allergy, but the conclusion is uncertain, since the azithromycin skin test concentration used is known to be irritating, and none of the skin test-positive patients were challenged.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a similar series of 45 pediatric patients referred for
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         allergy (urticaria, angioedema, and maculopapular rashes), 9 (20 percent) had immediate reactions, and 36 had delayed reactions [
         <a href="#rid28">
          28
         </a>
         ]. Twenty of the patients were skin tested (up to 0.05 mg/mL intradermally), and all the patients underwent graded challenge with clarithromycin (one day for immediate reactors, five days for delayed reactors). Nine patients had positive skin tests, but none of them reacted on challenge. Two of 11 patients with negative skin tests developed urticaria on challenge. None of the 25 patients who were challenged without prior skin tested reacted. Hence, overall, only 2 of 45 (4 percent) of the patients were confirmed to be allergic, and skin testing performance was poor (PPV 0 percent, NPV 82 percent, sensitivity 0 percent, and specificity 50 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Another series consisted of 107 consecutive patients evaluated over a five-year period for suspected macrolide allergy [
         <a href="#rid6">
          6
         </a>
         ]. Eleven percent of reactions were immediate, 66 percent were delayed, and 23 percent were of unknown type. Five percent of the patients reported anaphylaxis, 53 percent reported urticaria and/or angioedema, 24 percent reported maculopapular rashes, and the rest were unknown. Skin testing (prick-puncture and intradermal) was carried out in only 33 patients using macrolide concentrations of 10 mg/mL (there is no mention of a control group). The other 74 patients were not skin tested. All the patients (regardless of skin test results) underwent single-blinded challenges with the culprit macrolide, and 8 of 107 (7.5 percent) reacted, one-half of whom had positive skin tests. In the challenge-negative group, 7 of 25 had positive skin tests. The eight reactions to challenge consisted of four maculopapular rashes, three urticarial reactions, and one case of anaphylaxis, although all were easily treated. Although the study's usefulness was limited by the low percentage of patients skin tested, the PPV of skin testing was 36 percent, NPV was 82 percent, sensitivity was 50 percent, and specificity was 72 percent.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3201877">
         <span class="h3">
          Graded challenge
         </span>
         <span class="headingEndMark">
          —
         </span>
         Graded challenge can be performed with or without prior skin testing, as discussed previously. It is useful for patients with either immediate or delayed past reactions. We prefer to challenge with
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         (rather than other macrolides) because it is available in both parenteral and oral formulations to treat future infections. Also, azithromycin has a more favorable gastrointestinal side effect profile compared with other macrolides. Patients with recent severe anaphylaxis should undergo rapid desensitization rather than graded challenge. (See
         <a class="medical medical_review" href="/z/d/html/2071.html" rel="external">
          "Rapid drug desensitization for immediate hypersensitivity reactions"
         </a>
         .)
        </p>
        <p>
         A representative macrolide graded challenge starts with 1/100
         <sup>
          th
         </sup>
         of the full dose and includes two to four steps until the full dose is reached. The degree of caution exercised may be adjusted based upon the severity of the historical reaction and the time elapsed since the reaction.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with immediate past reactions, such as a pruritic rash five years ago, an oral challenge with 2.5 mg, 25 mg, and 250 mg
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         , given hourly under observation would be suitable.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with delayed past reactions, the author's approach to challenge is to administer 25 mg
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         , observe for one hour, and then administer 250 mg, and observe for an additional hour. The reason for giving the initial dose under observation is the author's experience that, unless the patient knows that the drug can be safely ingested, there may be continued reluctance to use it in the future. A delayed reaction may occur during the 24 hours following the initial dose, and patients should be instructed to inform the clinician if this occurs.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         It is important to understand the limitations of challenge procedures for delayed maculopapular exanthema. Some of these reactions only recur after several days of therapy, and there is no practical way to elicit such reactions without administering a full therapeutic course. This should be explained to patients.
        </p>
        <p>
        </p>
        <p>
         After completion of the challenge procedure, patients who do not need the antibiotic at that time can simply take it normally in the future. Patients who need macrolide therapy at that time can continue the treatment for a full course.
        </p>
        <p>
         If a patient develops a mild exanthema during future courses of therapy, it may be reasonable to attempt to continue the drug and add antihistamine therapy, provided that the reaction lacks any worrisome features. This approach has not been formally studied and is only appropriate when the benefit of continued treatment clearly outweighs the risk of further reaction. Such situations require clinical judgement.
        </p>
        <p class="headingAnchor" id="H3201898">
         <span class="h1">
          AMINOGLYCOSIDES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Aminoglycosides have been in widespread clinical use since the 1940s and are generally well-tolerated. The main nonallergic adverse effects are nephrotoxicity and ototoxicity, as reviewed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/483.html" rel="external">
          "Aminoglycosides", section on 'Toxicity'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8609049">
         <span class="h2">
          Types of reactions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Aminoglycosides uncommonly cause allergic reactions, with the notable exception of allergic contact dermatitis (a type IV immunologic reaction) to topical aminoglycosides. Allergic contact dermatitis due to topical
         <a class="drug drug_general" data-topicid="9686" href="/z/d/drug information/9686.html" rel="external">
          neomycin
         </a>
         is common, and neomycin is included in the T.R.U.E. TEST panel and other commercial patch test products [
         <a href="#rid32">
          32,33
         </a>
         ].
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          Gentamicin
         </a>
         in eye and ear drops is implicated in contact dermatitis less often [
         <a href="#rid34">
          34
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16691.html" rel="external">
          "Patch testing"
         </a>
         .)
        </p>
        <p>
         Immunoglobulin E (IgE)-mediated reactions to aminoglycosides are rare, with only a few reported cases of anaphylaxis [
         <a href="#rid35">
          35-42
         </a>
         ].
        </p>
        <p>
         Allergic cross-reactivity among aminoglycosides in all types of allergic reactions appears to be extensive, based primarily on patch test data for contact dermatitis and on anecdotal reports of patients developing reactions of other types from multiple aminoglycosides [
         <a href="#rid37">
          37,43-45
         </a>
         ]. Therefore, patients allergic to one aminoglycoside should avoid the entire class.
        </p>
        <p>
         The evaluation of patients with possible allergy to aminoglycosides is warranted only if there is an imminent need for treatment with this class of antibiotics. This clinical scenario is most often encountered in patients with cystic fibrosis.
        </p>
        <p class="headingAnchor" id="H28267705">
         <span class="h2">
          Skin testing for immediate reactions
         </span>
         <span class="headingEndMark">
          —
         </span>
         In two patients with immediate reactions, IgE-mediated allergy was confirmed by positive prick-puncture skin testing with
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         [
         <a href="#rid35">
          35,37,41,42
         </a>
         ]. If skin testing is pursued, the highest nonirritating concentration of aminoglycoside should be used [
         <a href="#rid29">
          29
         </a>
         ]. We suggest the following concentrations for both prick-puncture and intradermal testing:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          Gentamicin
         </a>
         – 0.4 mg/mL (1:100 dilution of the commercially available 40 mg/mL intravenous [IV] solution).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          Tobramycin
         </a>
         – 4 mg/mL (1:10 dilution of commercially available 40 mg/mL IV solution).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">
          Streptomycin
         </a>
         – 0.1 to 1 mg/mL initially [
         <a href="#rid39">
          39
         </a>
         ], potentially increasing (if negative) to concentrations as high as 20 mg/mL [
         <a href="#rid46">
          46
         </a>
         ]. Of note, there is a case report of anaphylaxis to prick-puncture testing with 1 mg/mL, and irritant properties of higher concentrations have not been studied [
         <a href="#rid40">
          40,46
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Patients with IgE-mediated allergy to aminoglycosides who require the drug for severe infections and for whom there are no suitable alternatives may undergo rapid desensitization. This has been successfully accomplished with IV
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         and with inhaled tobramycin [
         <a href="#rid45">
          45,47
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2071.html" rel="external">
          "Rapid drug desensitization for immediate hypersensitivity reactions"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H28267712">
         <span class="h2">
          Patch testing for contact dermatitis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patch testing is valuable in patients with contact dermatitis-type reactions, and since
         <a class="drug drug_general" data-topicid="9686" href="/z/d/drug information/9686.html" rel="external">
          neomycin
         </a>
         is one of the most common contact allergens, it is included in the commercially available T.R.U.E. TEST panel [
         <a href="#rid33">
          33
         </a>
         ]. Patch testing is performed by some allergists and by dermatologists. (See
         <a class="medical medical_review" href="/z/d/html/16691.html" rel="external">
          "Patch testing"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2416917">
         <span class="h1">
          TETRACYCLINES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The
         <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">
          tetracycline
         </a>
         group of antibiotics includes tetracycline,
         <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">
          minocycline
         </a>
         ,
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         ,
         <a class="drug drug_general" data-topicid="9328" href="/z/d/drug information/9328.html" rel="external">
          demeclocycline
         </a>
         , and
         <a class="drug drug_general" data-topicid="9458" href="/z/d/drug information/9458.html" rel="external">
          tigecycline
         </a>
         . Newer agents include
         <a class="drug drug_general" data-topicid="118878" href="/z/d/drug information/118878.html" rel="external">
          eravacycline
         </a>
         ,
         <a class="drug drug_general" data-topicid="119255" href="/z/d/drug information/119255.html" rel="external">
          sarecycline
         </a>
         , and
         <a class="drug drug_general" data-topicid="119253" href="/z/d/drug information/119253.html" rel="external">
          omadacycline
         </a>
         . Nonallergic adverse effects, such as photosensitivity, are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/494.html" rel="external">
          "Tetracyclines", section on 'Adverse reactions'
         </a>
         .)
        </p>
        <p>
         Immunoglobulin E (IgE)-mediated reactions due to the tetracyclines are rare, with only a few published case reports and small series [
         <a href="#rid48">
          48-52
         </a>
         ]. In a report of ten patients, investigators performed intradermal skin testing when prick-puncture testing was negative, whereas only prick-puncture testing had been reported in earlier studies [
         <a href="#rid52">
          52
         </a>
         ]. The non-irritating intradermal concentrations of
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         ,
         <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">
          minocycline
         </a>
         , and
         <a class="drug drug_general" data-topicid="9458" href="/z/d/drug information/9458.html" rel="external">
          tigecycline
         </a>
         (in non-allergic controls) were found to be 0.001 mg/mL, 0.002 mg/mL, and 0.1 mg/mL, respectively. Five subjects with negative skin testing tolerated graded challenge, but the positive predictive value was not determined, since all subjects with positive skin tests were either successfully desensitized or avoided the drug.
        </p>
        <p class="headingAnchor" id="H2416924">
         <span class="h2">
          Minocycline
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">
          Minocycline
         </a>
         appears to be a relatively common cause of severe non-IgE-mediated reactions and is implicated far more often than other tetracyclines [
         <a href="#rid53">
          53
         </a>
         ]. This may be because minocycline is metabolized to reactive intermediates, whereas
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         and
         <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">
          tetracycline
         </a>
         are not [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p>
         Reactions attributed to
         <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">
          minocycline
         </a>
         include the following [
         <a href="#rid53">
          53-59
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Drug reaction with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome (DRESS/DiHS) – In a seven-year prospective study evaluating the incidence of DRESS/DiHS,
         <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">
          minocycline
         </a>
         was the third most common cause, after
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         and
         <a class="drug drug_general" data-topicid="8439" href="/z/d/drug information/8439.html" rel="external">
          allopurinol
         </a>
         [
         <a href="#rid60">
          60-63
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16420.html" rel="external">
          "Drug reaction with eosinophilia and systemic symptoms (DRESS)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Serum sickness-like reactions [
         <a href="#rid53">
          53,55
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2078.html" rel="external">
          "Serum sickness and serum sickness-like reactions"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Stevens-Johnson syndrome (SJS) [
         <a href="#rid59">
          59
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2091.html" rel="external">
          "Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Eosinophilic pneumonia [
         <a href="#rid58">
          58
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5715.html" rel="external">
          "Overview of pulmonary eosinophilia", section on 'Medications and toxins'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Drug-induced lupus –
         <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">
          Minocycline
         </a>
         is the only
         <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">
          tetracycline
         </a>
         associated with drug-induced lupus [
         <a href="#rid53">
          53,55,64
         </a>
         ]. This observation might be due to the fact that minocycline is prescribed much more commonly for long-term use, especially for treatment of acne, whereas
         <a class="drug drug_general" data-topicid="9393" href="/z/d/drug information/9393.html" rel="external">
          doxycycline
         </a>
         and tetracycline are more likely prescribed for acute infections with short duration of therapy. It is also possible that minocycline metabolism produces more reactive intermediates capable of possibly binding to major histocompatibility complex (MHC) class II molecules leading to autoimmune reactions. It is important for clinicians to be aware that there may be a long interval between the start of therapy and onset of symptoms. The average time to onset of minocycline-induced lupus is two years after initiation of therapy, and it may be delayed as long as six years [
         <a href="#rid53">
          53
         </a>
         ]. In contrast, the other non-IgE-mediated allergic reactions mentioned above typically appear within one month of initiation of therapy [
         <a href="#rid53">
          53
         </a>
         ]. Minocycline-induced lupus afflicts the same population (predominantly females) as idiopathic lupus. There are no data to support or refute the safety of minocycline or other drugs associated with drug-induced lupus in patients with idiopathic lupus. However, standard practice is to avoid the tetracyclines in patients with lupus. Drug-induced lupus is reviewed in more detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/4677.html" rel="external">
          "Drug-induced lupus"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2416931">
         <span class="h2">
          Cross-reactivity
         </span>
         <span class="headingEndMark">
          —
         </span>
         The extent of allergic cross-reactivity among tetracyclines has not been studied. Given that non-IgE-mediated allergic reactions to
         <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">
          minocycline
         </a>
         are often severe and the natural history of these reactions is unknown, it seems prudent to advise patients with history of severe hypersensitivity reactions to minocycline (or another
         <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">
          tetracycline
         </a>
         ) to avoid all tetracyclines unless there is a compelling reason for use of these drugs. However, there are anecdotal reports of patients with minocycline-induced hypersensitivity reactions who later tolerated other tetracyclines [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H8609829">
         <span class="h1">
          CLINDAMYCIN
         </span>
         <span class="headingEndMark">
          —
         </span>
         Allergic reactions to
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         are uncommon. Clindamycin is a frequent cause of gastrointestinal side effects and also one of the more common causes of
         <em>
          Clostridioides difficile
         </em>
         colitis, and patients may report these side effects as allergies, although they are not immunologic reactions. Nonallergic adverse effects of clindamycin are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/485.html" rel="external">
          "Clindamycin: An overview", section on 'Toxicity'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8609836">
         <span class="h2">
          Types of reactions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Maculopapular eruptions are reported more than any other type of hypersensitivity. In a retrospective review of inpatient pharmacy and medical records, allergic-type reactions were reported in 0.4 percent (14 of 3896) courses of
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         , seven of which were confounded by concurrent administration of other medications, including other antibiotics [
         <a href="#rid65">
          65
         </a>
         ]. Almost all of the reactions were maculopapular eruptions. There were no anaphylactic reactions and no severe non-IgE-mediated reactions.
        </p>
        <p>
         Based on available literature, anaphylactic reactions to
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         are rare [
         <a href="#rid66">
          66,67
         </a>
         ]. Severe non-IgE-mediated reactions, such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome (DRESS/DiHS) have been reported [
         <a href="#rid68">
          68-70
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H8609843">
         <span class="h2">
          Evaluation
         </span>
         <span class="headingEndMark">
          —
         </span>
         As with other antibiotics, evaluation of
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         allergy should start with a complete history and review of medical records if possible.
        </p>
        <p class="headingAnchor" id="H2418020">
         <span class="h3">
          Maculopapular eruptions
         </span>
         <span class="headingEndMark">
          —
         </span>
         If the reaction history is compatible with a possible maculopapular eruption, a graded challenge with
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         can be performed. A sample protocol for graded challenge with a drug that may have caused a maculopapular eruption in the past is found separately. (See
         <a class="medical medical_review" href="/z/d/html/2079.html" rel="external">
          "An approach to the patient with drug allergy", section on 'For delayed reactions'
         </a>
         .)
        </p>
        <p>
         Graded challenge with
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         is typically pursued only if patients are likely to require treatment with this antibiotic. This situation is unusual, since the types of bacteria and infections amenable to treatment with clindamycin are relatively narrow compared with other antibiotic classes. Successful desensitization has been described in rare patients who are confirmed to be allergic (eg, such as during graded challenge) and require treatment with clindamycin [
         <a href="#rid71">
          71
         </a>
         ].
        </p>
        <p>
         For patients with reactions to
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         as well as multiple other antibiotics, evaluation of allergies to the other antibiotics should usually be pursued first. This is because other antibiotics (such as penicillins, cephalosporins, and fluoroquinolones) have broader bacterial coverage (and are therefore more clinically useful), allergies to other antibiotics have a better defined natural history, and testing and challenge procedures are more established for other antibiotics.
        </p>
        <p>
         Neither skin testing nor patch testing appears to be useful for the evaluation of maculopapular eruptions to
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         , as demonstrated in the following studies [
         <a href="#rid72">
          72-74
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a series of 33 consecutive patients who developed maculopapular rashes while taking
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         , evaluation occurred within one year of the reaction in all cases [
         <a href="#rid72">
          72
         </a>
         ]. One-half of patients reported onset of symptoms on days 1 to 6 of the treatment course, the other one-half on day 6 or later. Twenty-seven of the reactions were graded as mild or moderate, and the rest were severe. All subjects underwent prick-puncture skin testing (which was read at 20 minutes and 72 hours) and patch testing, although intradermal skin testing was not performed. Prick-puncture and patch testing were found to be nonirritating in control subjects. Prick-puncture skin testing was negative at 20 minutes in all patients. Five patients had both positive prick-puncture skin tests at 72 hours and positive patch tests, and they were not challenged with clindamycin. Of the remaining 28 patients, 26 underwent graded oral challenges (2 refused) and 6 were positive (3 maculopapular rashes, 2 symmetrical intertriginous exanthems, and 1 fixed drug eruption).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a review of 31 patients with delayed-onset reactions temporally associated with
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         , all patients underwent prick and intradermal skin testing with readings at 20 minutes and 48 to 72 hours [
         <a href="#rid74">
          74
         </a>
         ]. None of the patients had positive skin tests at the 20-minute reading, whereas two patients were positive at 48 hours. All patients were challenged with a single dose of 150 mg of oral clindamycin. Ten of 31 (32 percent) experienced reactions. Eight occurred two to six hours after challenge and two occurred one to two days after challenge. The reactions consisted of eight pruritic maculopapular rashes, one urticaria, one angioedema, and no severe reactions. Of the two patients with positive-delayed skin tests, one reacted on challenge (maculopapular rash on day 2), and the other patient did not react. Thus, skin testing was not useful for the identification of clindamycin-allergic patients.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3201912">
         <span class="h1">
          METRONIDAZOLE
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          Metronidazole
         </a>
         is an imidazole with structural similarities to
         <a class="drug drug_general" data-topicid="9287" href="/z/d/drug information/9287.html" rel="external">
          clotrimazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">
          ketoconazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="16763" href="/z/d/drug information/16763.html" rel="external">
          miconazole
         </a>
         , and
         <a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">
          albendazole
         </a>
         . Nonallergic adverse effects are reviewed separately. (See
         <a class="medical medical_review" href="/z/d/html/464.html" rel="external">
          "Metronidazole: An overview", section on 'Toxicity'
         </a>
         .)
        </p>
        <p>
         Hypersensitivity reactions due to
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         are rare, with only a small number of case reports in the published literature [
         <a href="#rid75">
          75-84
         </a>
         ]. However, an array of different reaction types (both immediate and delayed) have been reported, including various generalized exanthems, fixed drug eruption [
         <a href="#rid80">
          80-82,85
         </a>
         ], serum sickness-like reaction [
         <a href="#rid83">
          83
         </a>
         ], Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) [
         <a href="#rid84">
          84
         </a>
         ], and anaphylaxis [
         <a href="#rid75">
          75
         </a>
         ].
        </p>
        <p>
         Based primarily on patch test data (and some challenges), there appears to be a moderate degree of allergic cross-reactivity between
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         and other imidazoles [
         <a href="#rid86">
          86-88
         </a>
         ]. Therefore, patients allergic to metronidazole should avoid other imidazoles, such as
         <a class="drug drug_general" data-topicid="9287" href="/z/d/drug information/9287.html" rel="external">
          clotrimazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">
          ketoconazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="16763" href="/z/d/drug information/16763.html" rel="external">
          miconazole
         </a>
         , and
         <a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">
          albendazole
         </a>
         .
        </p>
        <p class="headingAnchor" id="H3201919">
         <span class="h2">
          Skin testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         A small number of studies have described skin testing with
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         [
         <a href="#rid75">
          75,76
         </a>
         ]. Prick-puncture testing was positive in one case of anaphylaxis [
         <a href="#rid75">
          75
         </a>
         ], although other larger studies suggest that the sensitivity is low. In the largest series, 14 patients with a history of recent (&lt;1 year) cutaneous reactions to Rhodogil (metronidazole plus
         <a class="drug drug_general" data-topicid="10092" href="/z/d/drug information/10092.html" rel="external">
          spiramycin
         </a>
         ) underwent prick-puncture and intradermal skin testing (20-minute, 48-hour, and 96-hour readings) and oral challenges [
         <a href="#rid76">
          76
         </a>
         ]. Eleven patients were skin test-negative, but three of these reacted to a single-dose challenge of metronidazole, developing pruritic rashes and facial angioedema at 45 minutes, 1 hour, and 7 hours. The remaining 10 patients were skin test-negative and passed challenges with metronidazole and spiramycin. The one patient who was prick test-positive was not challenged.
        </p>
        <p>
         Thus, in patients in whom the suspicion of an immediate reaction is high based upon the clinical history, we suggest avoidance of all imidazoles in the future. If the patient requires a specific drug and there are no suitable alternatives, a desensitization procedure can be performed [
         <a href="#rid78">
          78,89,90
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2071.html" rel="external">
          "Rapid drug desensitization for immediate hypersensitivity reactions"
         </a>
         .)
        </p>
        <p>
         In patients whose history is not suggestive of a true hypersensitivity reaction or the reaction history is distant and mild, we suggest graded challenge to confirm lack of reactivity.
        </p>
        <p class="headingAnchor" id="H2514482338">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/109237.html" rel="external">
          "Society guideline links: Drug allergy and hypersensitivity"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3203245">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Macrolides, aminoglycosides, tetracyclines,
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         , and
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          metronidazole
         </a>
         infrequently cause hypersensitivity reactions, compared with penicillins, sulfonamides, and other classes of antimicrobials. (See
         <a class="local">
          'Overview'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Evaluation of a patient with a past drug reaction always begins with a careful clinical history to determine what type of adverse reaction the patient likely experienced. Hypersensitivity (allergic) reactions are adverse reactions that are mediated by the immune system. Referral to an expert in drug allergy is indicated in specific circumstances. (See
         <a class="local">
          'Referral'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The pathogenesis of hypersensitivity reactions to the antibiotics discussed in this review is not well-characterized, and none of the diagnostic tests used to evaluate patients with these reactions is standardized or validated. Thus, skin testing with the antibiotics discussed in this topic is much less informative than that performed to evaluate penicillin allergy. In some cases, the evaluation consists of a careful history and graded challenge. (See
         <a class="local">
          'Allergy evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Macrolides cause delayed-onset maculopapular exanthems in about 1 percent of treated patients, which is close to the rate in placebo-treated patients in many drug studies. Anaphylaxis and serious non-immunoglobulin E (IgE)-mediated reactions are rare. Skin testing is controversial, and graded challenge is often required for conclusive diagnosis, although there are usually alternate classes of antibiotics that can be substituted for macrolides. Patients who have reacted to one macrolide in the past may tolerate other macrolides. (See
         <a class="local">
          'Macrolides'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Aminoglycosides are well-tolerated as a group, with the exception of topical
         <a class="drug drug_general" data-topicid="9686" href="/z/d/drug information/9686.html" rel="external">
          neomycin
         </a>
         , which is a relatively common cause of allergic contact dermatitis and is included on many commercial patch testing panels. Rare cases of anaphylaxis have been confirmed with immediate-type skin testing. Cross-reactivity appears to be extensive, and patients are usually advised to avoid all aminoglycosides if they have had a significant reaction to one. (See
         <a class="local">
          'Aminoglycosides'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among
         <a class="drug drug_general" data-topicid="9986" href="/z/d/drug information/9986.html" rel="external">
          tetracycline
         </a>
         drugs,
         <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">
          minocycline
         </a>
         causes more hypersensitivity reactions than all others. Minocycline has been implicated in an array of serious non-IgE-mediated reactions, such as drug reaction with eosinophilia and systemic symptoms/drug-induced hypersensitivity syndrome (DRESS/DiHS), drug-induced lupus, and toxic epidermal necrolysis (TEN). Among the other drugs, rare cases of anaphylaxis have been confirmed with immediate-type skin testing. Cross-reactivity is not well-studied, so patients with past reactions are usually advised to avoid the entire group if possible. (See
         <a class="local">
          'Tetracyclines'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The most common reaction to
         <a class="drug drug_general" data-topicid="9275" href="/z/d/drug information/9275.html" rel="external">
          clindamycin
         </a>
         is maculopapular exanthem. Neither skin testing nor patch testing appears to be useful for the evaluation of this reaction. (See
         <a class="local">
          'Clindamycin'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9646" href="/z/d/drug information/9646.html" rel="external">
          Metronidazole
         </a>
         has been anecdotally implicated in several types of rare hypersensitivity reactions, including anaphylaxis, fixed drug eruption, serum sickness-like reaction, and Stevens-Johnson syndrome (SJS)/TEN. (See
         <a class="local">
          'Metronidazole'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Kuyucu S, Mori F, Atanaskovic-Markovic M, et al. Hypersensitivity reactions to non-betalactam antibiotics in children: an extensive review. Pediatr Allergy Immunol 2014; 25:534.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joint Task Force on Practice Parameters, American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma and Immunology, Joint Council of Allergy, Asthma and Immunology. Drug allergy: an updated practice parameter. Ann Allergy Asthma Immunol 2010; 105:259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johansson SG, Bieber T, Dahl R, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004; 113:832.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Naldi L, Conforti A, Venegoni M, et al. Cutaneous reactions to drugs. An analysis of spontaneous reports in four Italian regions. Br J Clin Pharmacol 1999; 48:839.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van der Linden PD, van der Lei J, Vlug AE, Stricker BH. Skin reactions to antibacterial agents in general practice. J Clin Epidemiol 1998; 51:703.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benahmed S, Scaramuzza C, Messaad D, et al. The accuracy of the diagnosis of suspected macrolide antibiotic hypersensitivity: results of a single-blinded trial. Allergy 2004; 59:1130.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lammintausta K, Kortekangas-Savolainen O. Oral challenge in patients with suspected cutaneous adverse drug reactions: findings in 784 patients during a 25-year-period. Acta Derm Venereol 2005; 85:491.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mori F, Barni S, Pucci N, et al. Sensitivity and specificity of skin tests in the diagnosis of clarithromycin allergy. Ann Allergy Asthma Immunol 2010; 104:417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seitz CS, Bröcker EB, Trautmann A. Suspicion of macrolide allergy after treatment of infectious diseases including Helicobacter pylori: results of allergological testing. Allergol Immunopathol (Madr) 2011; 39:193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gangemi S, Ricciardi L, Fedele R, et al. Immediate reaction to clarithromycin. Allergol Immunopathol (Madr) 2001; 29:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Holmes NE, Hodgkinson M, Dendle C, Korman TM. Report of oral clarithromycin desensitization. Br J Clin Pharmacol 2008; 66:323.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jorro G, Morales C, Brasó JV, Peláez A. Anaphylaxis to erythromycin. Ann Allergy Asthma Immunol 1996; 77:456.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pascual C, Crespo JF, Quiralte J, et al. In vitro detection of specific IgE antibodies to erythromycin. J Allergy Clin Immunol 1995; 95:668.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mori F, Pecorari L, Pantano S, et al. Azithromycin anaphylaxis in children. Int J Immunopathol Pharmacol 2014; 27:121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Treadway G, Pontani D. Paediatric safety of azithromycin: worldwide experience. J Antimicrob Chemother 1996; 37 Suppl C:143.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khurana CM. A multicenter, randomized, open label comparison of azithromycin and amoxicillin/clavulanate in acute otitis media among children attending day care or school. Pediatr Infect Dis J 1996; 15:S24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McLinn S. A multicenter, double blind comparison of azithromycin and amoxicillin/ clavulanate for the treatment of acute otitis media in children. Pediatr Infect Dis J 1996; 15:S20.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Block SL, Arrieta A, Seibel M, et al. Single-dose (30 mg/kg) azithromycin compared with 10-day amoxicillin/clavulanate for the treatment of uncomplicated acute otitis media: a double-blind, placebo-controlled, randomized clinical trial. Curr Ther Res Clin Exp 2003; 64:30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arrieta A, Arguedas A, Fernandez P, et al. High-dose azithromycin versus high-dose amoxicillin-clavulanate for treatment of children with recurrent or persistent acute otitis media. Antimicrob Agents Chemother 2003; 47:3179.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dagan R, Johnson CE, McLinn S, et al. Bacteriologic and clinical efficacy of amoxicillin/clavulanate vs. azithromycin in acute otitis media. Pediatr Infect Dis J 2000; 19:95.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arguedas A, Soley C, Kamicker BJ, Jorgensen DM. Single-dose extended-release azithromycin versus a 10-day regimen of amoxicillin/clavulanate for the treatment of children with acute otitis media. Int J Infect Dis 2011; 15:e240.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Araújo L, Demoly P. Macrolides allergy. Curr Pharm Des 2008; 14:2840.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Borja JM, Galindo PA, Feo F, et al. Maculopapular exanthema from diacetyl-midecamycin (MOM). Allergy 1998; 53:1004.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Igea JM, Lázaro M. Hypersensitivity reaction to clarithromycin. Allergy 1998; 53:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Igea JM, Quirce S, de la Hoz B, et al. Adverse cutaneous reactions due to macrolides. Ann Allergy 1991; 66:216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sánchez-Morillas L, Laguna-Martínez JJ, Reaño-Martos M, et al. Hypersensitivity to spiramycin with good tolerance of other macrolides. J Investig Allergol Clin Immunol 2007; 17:417.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swamy N, Laurie SA, Ruiz-Huidobro E, Khan DA. Successful clarithromycin desensitization in a multiple macrolide-allergic patient. Ann Allergy Asthma Immunol 2010; 105:489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cavkaytar O, Karaatmaca B, Yilmaz EA, et al. Testing for clarithromycin hypersensitivity: A diagnostic challenge in childhood. J Allergy Clin Immunol Pract 2016; 4:330.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Empedrad R, Darter AL, Earl HS, Gruchalla RS. Nonirritating intradermal skin test concentrations for commonly prescribed antibiotics. J Allergy Clin Immunol 2003; 112:629.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brož P, Harr T, Hecking C, et al. Nonirritant intradermal skin test concentrations of ciprofloxacin, clarithromycin, and rifampicin. Allergy 2012; 67:647.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barni S, Butti D, Mori F, et al. Azithromycin is more allergenic than clarithromycin in children with suspected hypersensitivity reaction to macrolides. J Investig Allergol Clin Immunol 2015; 25:128.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Menezes de Pádua CA, Schnuch A, Lessmann H, et al. Contact allergy to neomycin sulfate: results of a multifactorial analysis. Pharmacoepidemiol Drug Saf 2005; 14:725.
          </a>
         </li>
         <li class="breakAll">
          The allergens found in various commercial testing kits can be accessed at: http://www.truetest.com/panelallergens.aspx (Accessed on May 31, 2012).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sánchez-Pérez J, López MP, De Vega Haro JM, García-Díez A. Allergic contact dermatitis from gentamicin in eyedrops, with cross-reactivity to kanamycin but not neomycin. Contact Dermatitis 2001; 44:54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Connolly M, McAdoo J, Bourke JF. Gentamicin-induced anaphylaxis. Ir J Med Sci 2007; 176:317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hall FJ. Anaphylaxis after gentamycin. Lancet 1977; 2:455.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schulze S, Wollina U. Gentamicin-induced anaphylaxis. Allergy 2003; 58:88.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Proebstle TM, Jugert FK, Merk HF, Gall H. Severe anaphylactic reaction to topical administration of framycetin. J Allergy Clin Immunol 1995; 96:429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Iikura M, Yamaguchi M, Hirai K, et al. Case report: streptomycin-induced anaphylactic shock during oocyte retrieval procedures for in vitro fertilization. J Allergy Clin Immunol 2002; 109:571.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Romano A, Viola M, Di Fonso M, et al. Anaphylaxis to streptomycin. Allergy 2002; 57:1087.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Christiansen IS, Pedersen P, Krøigaard M, et al. Anaphylaxis to intravenous gentamicin with suspected sensitization through gentamicin-loaded bone cement. J Allergy Clin Immunol Pract 2016; 4:1258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Henao CMG, Morales CIH, Villa RC, et al. Gentamicin induced anaphylaxis, a case report. World Allergy Organ J 2015; 8:A269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gehrig KA, Warshaw EM. Allergic contact dermatitis to topical antibiotics: Epidemiology, responsible allergens, and management. J Am Acad Dermatol 2008; 58:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Guin JD, Phillips D. Erythroderma from systemic contact dermatitis: a complication of systemic gentamicin in a patient with contact allergy to neomycin. Cutis 1989; 43:564.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spigarelli MG, Hurwitz ME, Nasr SZ. Hypersensitivity to inhaled TOBI following reaction to gentamicin. Pediatr Pulmonol 2002; 33:311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tinkelman DG, Bock SA. Anaphylaxis presumed to be caused by beef containing streptomycin. Ann Allergy 1984; 53:243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Earl HS, Sullivan TJ. Acute desensitization of a patient with cystic fibrosis allergic to both beta-lactam and aminoglycoside antibiotics. J Allergy Clin Immunol 1987; 79:477.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jang JW, Bae YJ, Kim YG, et al. A case of anaphylaxis to oral minocycline. J Korean Med Sci 2010; 25:1231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ogita A, Takada K, Kawana S. Case of anaphylaxis due to tetracycline hydrochloride. J Dermatol 2011; 38:597.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Okano M, Imai S. Anaphylactoid symptoms due to oral minocycline. Acta Derm Venereol 1996; 76:164.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raeder JC. Anaphylactoid reaction caused by intravenous doxycycline during general anesthesia and beta-blockade treatment. Drug Intell Clin Pharm 1984; 18:481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maciag MC, Ward SL, O'Connell AE, Broyles AD. Hypersensitivity to tetracyclines: Skin testing, graded challenge, and desensitization regimens. Ann Allergy Asthma Immunol 2020; 124:589.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shapiro LE, Knowles SR, Shear NH. Comparative safety of tetracycline, minocycline, and doxycycline. Arch Dermatol 1997; 133:1224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown RJ, Rother KI, Artman H, et al. Minocycline-induced drug hypersensitivity syndrome followed by multiple autoimmune sequelae. Arch Dermatol 2009; 145:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knowles SR, Shapiro L, Shear NH. Serious adverse reactions induced by minocycline. Report of 13 patients and review of the literature. Arch Dermatol 1996; 132:934.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maubec E, Wolkenstein P, Loriot MA, et al. Minocycline-induced DRESS: evidence for accumulation of the culprit drug. Dermatology 2008; 216:200.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robles DT, Leonard JL, Compton N, et al. Severe drug hypersensitivity reaction in a young woman treated with doxycycline. Dermatology 2008; 217:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sitbon O, Bidel N, Dussopt C, et al. Minocycline pneumonitis and eosinophilia. A report on eight patients. Arch Intern Med 1994; 154:1633.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yoon J, Lee SH, Kim TH, et al. Concurrence of Stevens-Johnson Syndrome and Bilateral Parotitis after Minocycline Therapy. Case Rep Dermatol 2010; 2:88.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muller P, Dubreil P, Mahé A, et al. Drug Hypersensitivity Syndrome in a West-Indian population. Eur J Dermatol 2003; 13:478.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kanno K, Sakai H, Yamada Y, Iizuka H. Drug-induced hypersensitivity syndrome due to minocycline complicated by severe myocarditis. J Dermatol 2014; 41:160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lan J, Lahoti A, Lew DB. A severe case of minocycline-induced DRESS resulting in liver transplantation and autoimmune sequelae. Ann Allergy Asthma Immunol 2016; 116:367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu PA, Anadkat MJ. Fever, eosinophilia, and death: a case of minocycline hypersensitivity. Cutis 2014; 93:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Masson C, Chevailler A, Pascaretti C, et al. Minocycline related lupus. J Rheumatol 1996; 23:2160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mazur N, Greenberger PA, Regalado J. Clindamycin hypersensitivity appears to be rare. Ann Allergy Asthma Immunol 1999; 82:443.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chiou CS, Lin SM, Lin SP, et al. Clindamycin-induced anaphylactic shock during general anesthesia. J Chin Med Assoc 2006; 69:549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bulloch MN, Baccas JT, Arnold S. Clindamycin-induced hypersensitivity reaction. Infection 2016; 44:357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Correia O, Chosidow O, Saiag P, et al. Evolving pattern of drug-induced toxic epidermal necrolysis. Dermatology 1993; 186:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fulghum DD, Catalano PM. Stevens-Johnson syndrome from clindamycin. JAMA 1973; 223:318.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller Quidley A, Bookstaver PB, Gainey AB, Gainey MD. Fatal clindamycin-induced drug rash with eosinophilia and systemic symptoms (DRESS) syndrome. Pharmacotherapy 2012; 32:e387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Esty B, Minnicozzi S, Chu EC, et al. Successful rapid oral clindamycin desensitization in a pediatric patient. J Allergy Clin Immunol Pract 2018; 6:2141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seitz CS, Bröcker EB, Trautmann A. Allergy diagnostic testing in clindamycin-induced skin reactions. Int Arch Allergy Immunol 2009; 149:246.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pereira N, Canelas MM, Santiago F, et al. Value of patch tests in clindamycin-related drug eruptions. Contact Dermatitis 2011; 65:202.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Notman MJ, Phillips EJ, Knowles SR, et al. Clindamycin skin testing has limited diagnostic potential. Contact Dermatitis 2005; 53:335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Asensio Sánchez T, Dávila I, Moreno E, et al. Anaphylaxis due to metronidazole with positive skin prick test. J Investig Allergol Clin Immunol 2008; 18:138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           García-Rubio I, Martínez-Cócera C, Santos Magadán S, et al. Hypersensitivity reactions to metronidazole. Allergol Immunopathol (Madr) 2006; 34:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knowles S, Choudhury T, Shear NH. Metronidazole hypersensitivity. Ann Pharmacother 1994; 28:325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kurohara ML, Kwong FK, Lebherz TB, Klaustermeyer WB. Metronidazole hypersensitivity and oral desensitization. J Allergy Clin Immunol 1991; 88:279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maize JC, Tomecki KJ. Pityriasis rosea-like drug eruption secondary to metronidazole. Arch Dermatol 1977; 113:1457.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Naik RP, Singh G. Fixed drug eruption due to metronidazole. Dermatologica 1977; 155:59.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shelley WB, Shelley ED. Fixed drug eruption due to metronidazole. Cutis 1987; 39:393.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Short KA, Fuller LC, Salisbury JR. Fixed drug eruption following metronidazole therapy and the use of topical provocation testing in diagnosis. Clin Exp Dermatol 2002; 27:464.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weart CW, Hyman LC. Serum sickness associated with metronidazole. South Med J 1983; 76:410.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mazumdar G, Shome K. Stevens-Johnson syndrome following use of metronidazole in a dental patient. Indian J Pharmacol 2014; 46:121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kumar N, Sundriyal D, Walia M, Trisal D. Metronidazole-induced fixed drug eruption. BMJ Case Rep 2013; 2013.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kanwar AJ, Sharma R, Rajagopalan M, Kaur S. Fixed drug eruption due to tinidazole with cross-reactivity with metronidazole. Dermatologica 1990; 180:277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mishra D, Mobashir M, Zaheer MS. Fixed drug eruption and cross-reactivity between tinidazole and metronidazole. Int J Dermatol 1990; 29:740.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thami GP, Kanwar AJ. Fixed drug eruption due to metronidazole and tinidazole without cross-sensitivity to secnidazole. Dermatology 1998; 196:368.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gendelman SR, Pien LC, Gutta RC, Abouhassan SR. Modified oral metronidazole desensitization protocol. Allergy Rhinol (Providence) 2014; 5:66.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Helms DJ, Mosure DJ, Secor WE, Workowski KA. Management of trichomonas vaginalis in women with suspected metronidazole hypersensitivity. Am J Obstet Gynecol 2008; 198:370.e1.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 84000 Version 15.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25201401" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Hypersensitivity reactions to non-betalactam antibiotics in children: an extensive review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20934625" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Drug allergy: an updated practice parameter.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15131563" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10594488" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Cutaneous reactions to drugs. An analysis of spontaneous reports in four Italian regions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9743319" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Skin reactions to antibacterial agents in general practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15355479" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : The accuracy of the diagnosis of suspected macrolide antibiotic hypersensitivity: results of a single-blinded trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16396795" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Oral challenge in patients with suspected cutaneous adverse drug reactions: findings in 784 patients during a 25-year-period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20486332" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Sensitivity and specificity of skin tests in the diagnosis of clarithromycin allergy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21269750" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Suspicion of macrolide allergy after treatment of infectious diseases including Helicobacter pylori: results of allergological testing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11449533" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Immediate reaction to clarithromycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18460032" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Report of oral clarithromycin desensitization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8970433" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Anaphylaxis to erythromycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7897148" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : In vitro detection of specific IgE antibodies to erythromycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24674687" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Azithromycin anaphylaxis in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8818855" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Paediatric safety of azithromycin: worldwide experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8878243" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : A multicenter, randomized, open label comparison of azithromycin and amoxicillin/clavulanate in acute otitis media among children attending day care or school.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8878242" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : A multicenter, double blind comparison of azithromycin and amoxicillin/ clavulanate for the treatment of acute otitis media in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24944351" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Single-dose (30 mg/kg) azithromycin compared with 10-day amoxicillin/clavulanate for the treatment of uncomplicated acute otitis media: a double-blind, placebo-controlled, randomized clinical trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14506028" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : High-dose azithromycin versus high-dose amoxicillin-clavulanate for treatment of children with recurrent or persistent acute otitis media.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10693993" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Bacteriologic and clinical efficacy of amoxicillin/clavulanate vs. azithromycin in acute otitis media.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21269858" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Single-dose extended-release azithromycin versus a 10-day regimen of amoxicillin/clavulanate for the treatment of children with acute otitis media.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18991703" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Macrolides allergy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9821484" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Maculopapular exanthema from diacetyl-midecamycin (MOM).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9491242" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Hypersensitivity reaction to clarithromycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1706568" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Adverse cutaneous reactions due to macrolides.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18088029" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Hypersensitivity to spiramycin with good tolerance of other macrolides.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21130389" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Successful clarithromycin desensitization in a multiple macrolide-allergic patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26489714" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Testing for clarithromycin hypersensitivity: A diagnostic challenge in childhood.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13679828" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Nonirritating intradermal skin test concentrations for commonly prescribed antibiotics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22435670" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Nonirritant intradermal skin test concentrations of ciprofloxacin, clarithromycin, and rifampicin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25997306" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Azithromycin is more allergenic than clarithromycin in children with suspected hypersensitivity reaction to macrolides.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15880442" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Contact allergy to neomycin sulfate: results of a multifactorial analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15880442" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Contact allergy to neomycin sulfate: results of a multifactorial analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11156029" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Allergic contact dermatitis from gentamicin in eyedrops, with cross-reactivity to kanamycin but not neomycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17724569" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Gentamicin-induced anaphylaxis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/70664" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Anaphylaxis after gentamycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12580818" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Gentamicin-induced anaphylaxis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7560649" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Severe anaphylactic reaction to topical administration of framycetin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11898008" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Case report: streptomycin-induced anaphylactic shock during oocyte retrieval procedures for in vitro fertilization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12359019" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Anaphylaxis to streptomycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27523275" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Anaphylaxis to intravenous gentamicin with suspected sensitization through gentamicin-loaded bone cement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Gentamicin induced anaphylaxis, a case report
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18158924" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Allergic contact dermatitis to topical antibiotics: Epidemiology, responsible allergens, and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2526007" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Erythroderma from systemic contact dermatitis: a complication of systemic gentamicin in a patient with contact allergy to neomycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11921461" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Hypersensitivity to inhaled TOBI following reaction to gentamicin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6476483" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Anaphylaxis presumed to be caused by beef containing streptomycin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3819228" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Acute desensitization of a patient with cystic fibrosis allergic to both beta-lactam and aminoglycoside antibiotics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20676339" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : A case of anaphylaxis to oral minocycline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21352288" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Case of anaphylaxis due to tetracycline hydrochloride.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8740283" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Anaphylactoid symptoms due to oral minocycline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6145571" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Anaphylactoid reaction caused by intravenous doxycycline during general anesthesia and beta-blockade treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32087343" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Hypersensitivity to tetracyclines: Skin testing, graded challenge, and desensitization regimens.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9382560" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Comparative safety of tetracycline, minocycline, and doxycycline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19153345" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Minocycline-induced drug hypersensitivity syndrome followed by multiple autoimmune sequelae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8712844" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Serious adverse reactions induced by minocycline. Report of 13 patients and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18182810" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Minocycline-induced DRESS: evidence for accumulation of the culprit drug.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18332631" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Severe drug hypersensitivity reaction in a young woman treated with doxycycline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8031212" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Minocycline pneumonitis and eosinophilia. A report on eight patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21103193" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Concurrence of Stevens-Johnson Syndrome and Bilateral Parotitis after Minocycline Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14693494" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Drug Hypersensitivity Syndrome in a West-Indian population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24471460" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Drug-induced hypersensitivity syndrome due to minocycline complicated by severe myocarditis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26782675" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : A severe case of minocycline-induced DRESS resulting in liver transplantation and autoimmune sequelae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24605348" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Fever, eosinophilia, and death: a case of minocycline hypersensitivity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8970057" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Minocycline related lupus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10353574" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Clindamycin hypersensitivity appears to be rare.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17116619" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Clindamycin-induced anaphylactic shock during general anesthesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26216470" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Clindamycin-induced hypersensitivity reaction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8435514" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Evolving pattern of drug-induced toxic epidermal necrolysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Stevens-Johnson syndrome from clindamycin
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23165860" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Fatal clindamycin-induced drug rash with eosinophilia and systemic symptoms (DRESS) syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29655773" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Successful rapid oral clindamycin desensitization in a pediatric patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19218817" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Allergy diagnostic testing in clindamycin-induced skin reactions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21689110" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Value of patch tests in clindamycin-related drug eruptions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16364122" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Clindamycin skin testing has limited diagnostic potential.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18447147" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Anaphylaxis due to metronidazole with positive skin prick test.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16606549" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Hypersensitivity reactions to metronidazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8193418" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Metronidazole hypersensitivity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1880329" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Metronidazole hypersensitivity and oral desensitization.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/911179" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Pityriasis rosea-like drug eruption secondary to metronidazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/144074" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Fixed drug eruption due to metronidazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2953560" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Fixed drug eruption due to metronidazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12372086" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Fixed drug eruption following metronidazole therapy and the use of topical provocation testing in diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6828915" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Serum sickness associated with metronidazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24550598" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Stevens-Johnson syndrome following use of metronidazole in a dental patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24217927" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Metronidazole-induced fixed drug eruption.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2141581" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Fixed drug eruption due to tinidazole with cross-reactivity with metronidazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2148563" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Fixed drug eruption and cross-reactivity between tinidazole and metronidazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9621157" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Fixed drug eruption due to metronidazole and tinidazole without cross-sensitivity to secnidazole.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24612959" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Modified oral metronidazole desensitization protocol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18221927" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Management of trichomonas vaginalis in women with suspected metronidazole hypersensitivity.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
